Dark Forest Capital Management LP increased its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 86.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,784 shares of the medical instruments supplier's stock after buying an additional 1,291 shares during the period. Dark Forest Capital Management LP's holdings in Insulet were worth $727,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of PODD. SBI Securities Co. Ltd. acquired a new position in shares of Insulet in the 4th quarter valued at $36,000. SRS Capital Advisors Inc. grew its position in Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after acquiring an additional 56 shares during the period. Friedenthal Financial purchased a new position in shares of Insulet in the 4th quarter worth about $57,000. Assetmark Inc. lifted its stake in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares in the last quarter. Finally, Blue Trust Inc. increased its position in Insulet by 117.3% during the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after purchasing an additional 149 shares in the last quarter.
Insulet Price Performance
Insulet stock traded down $1.02 during trading hours on Wednesday, hitting $250.25. 216,979 shares of the company traded hands, compared to its average volume of 714,259. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The firm has a market cap of $17.57 billion, a P/E ratio of 43.08, a P/E/G ratio of 3.62 and a beta of 1.30. The firm's 50-day simple moving average is $258.98 and its two-hundred day simple moving average is $262.02. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.
Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. As a group, analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. The trade was a 36.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.47% of the company's stock.
Wall Street Analysts Forecast Growth
PODD has been the subject of several recent research reports. Canaccord Genuity Group increased their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Wells Fargo & Company set a $322.00 target price on shares of Insulet in a research report on Monday. Citigroup lifted their target price on Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Stifel Nicolaus lifted their price objective on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a report on Friday, February 21st. Finally, Raymond James restated an "outperform" rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $292.06.
Check Out Our Latest Analysis on Insulet
Insulet Company Profile
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Featured Stories
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
